Success Stories

Background
Sarah is a 52-year-old woman diagnosed with breast cancer. A core biopsy of her primary tumor showed that the tumor was HER2-negative and ER-positive. Based on her molecular profile, she was appropriately treated for ER+ breast cancer. Sarah had been disease-free for about 2 years after treatment for her initial cancer when she visited her oncologist, Dr. Thomas as a follow-up due to some shortness of breath. Through her work-up and imaging studies, it was discovered that the cancer had recurred, this time with lesions in Sarah’s lung.

“Can we do another biopsy?”
Dr. Thomas was concerned about whether they would be able to get enough tissue from a surgical biopsy of the lung lesion. There were additional concerns about the location of the lesion, and any adverse effects that may occur from the re-biopsy procedure. Sarah had already been scheduled for a biopsy when her doctor considered an alternative approach. Dr. Thomas ordered a liquid biopsy from Biocept.

Establishing biomarker status with a simple blood test
Sarah’s doctor explained that a “liquid biopsy” was really just a simple blood test and only required a sample of blood from Sarah. It would spare her from undergoing another biopsy and the potential adverse effects that may have resulted due to the location of her lesion. The blood sample was sent to Biocept’s laboratory to be tested for established, clinically actionable biomarkers, including HER2 and ER. Dr. Thomas received Sarah’s results 5 days later and her results were both HER2positive and ER-positive.

A liquid biopsy reveals tumor heterogeneity
After considering all therapy options, Dr. Thomas decided to treat Sarah based on the results of the liquid biopsy with a combination therapy including anti-HER2 therapy and chemotherapy. Sarah responded well to this regimen and is in remission.

More effective treatment thanks to a liquid biopsy
Sarah was able to receive the appropriate standard of care therapy without an invasive lung biopsy. Through Biocept’s test, Sarah doctors were able to determine the true biology of her tumor and concluded that she would benefit from the anti-HER2 therapy regimen.

Background
Michelle is a 79-year-old grandmother and is retired in Florida. She was diagnosed with breast cancer approximately 6 years ago. A core biopsy of her primary tumor showed that the tumor was HER2-positive and ER-positive. Based on her molecular profile, she was appropriately treated for her breast cancer. Michelle had been disease-free for many years until she felt some bone pain that lead her to the doctor. After a thorough work up and imaging study, it was determined that Michelle’s cancer had likely recurred and metastasized to her bones.

“Can we do another biopsy?”
For patients with lesions to the bone, a biopsy is routine and possible. However in Michelle’s case, the HER2 result that was positive on her primary tumor showed up negative on the bone lesion. There were some concerns that the laboratory process using decalcification for the biopsy sample may have made it difficult to obtain the HER2 results. Michelle’s oncologist recommended ordering a liquid biopsy from Biocept.

Establishing biomarker status with a simple blood test
Michelle was told that through a “liquid biopsy,” a simple test that only required a sample of blood from Michelle, they might be able to retest the HER2 status without obtaining another biopsy of her bone lesions. It would spare her from the pain and discomfort of undergoing another biopsy. The blood sample was sent to Biocept’s laboratory to be tested for established, clinically actionable biomarkers, including HER2 and ER. Michelle’s oncologist received her results 5 days later and her results were positive for HER2, as they were on her primary tumor.

More effective treatment thanks to a liquid biopsy
Michelle was able to receive the appropriate standard of care therapy without the physician needing to go back into her bone to obtain aa additional biopsy. Through Biocept’s test, Michelle’s doctors were able to determine the true biology of her tumor and concluded that she would benefit from the anti-HER therapy that she needed to fight her breast cancer.

Background
Lisa is a 58-year-old and recently diagnosed with early stage breast cancer. A core biopsy of her primary tumor showed that the tumor was HER2-negative. Based on the stage and the presentation of her disease, she was a good candidate for neo-adjuvant therapy.

“Could we have missed this patient’s HER2 status?”
For patients with small core biopsies, there exists the possibility that due to the heterogeneity of disease, a small biopsy can miss areas of tumor that are positive for HER2 (and other critical biomarkers). Lisa’s doctor was familiar with ordering a liquid biopsy test from Biocept.

Establishing biomarker status with a simple blood test
Lisa was told that through a “liquid biopsy,” a simple test that only required a sample of blood, they could double check to confirm that they had not missed any HER2 positive cells. Finding HER2 positivity in early stage breast cancer patients who are candidates for neo-adjuvant therapy can drastically change the treatment options. The blood sample was sent to Biocept’s laboratory to be tested for established, clinically actionable biomarkers, including HER2 and ER. Doctors received Lisa’s results 5 days later and her results were positive for HER2 tumor cells circulating in the blood.

More effective treatment thanks to a liquid biopsy
Lisa still received neo-adjuvant therapy, but now it was with an anti-HER2 agent regimen. Through Biocept’s test, Lisa’s doctors were able to determine the true biology of her tumor and concluded that she would benefit from the anti-HER2 therapy that she needed to fight her breast cancer. This change to targeted therapy generally increases her likelihood of disease free survival while reducing side effects.